Torrent Pharma Q2 net profit dips 12 pc to Rs 179 crore

New Delhi: Drug firm Torrent Pharmaceuticals has reported a 12.25 per cent dip in its consolidated net profit to Rs 179 crore for the quarter ended September 2018 due to one-time impact of a product recall in the US and rupee depreciation. The company had posted a net profit of Rs 204 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a statement.

Its total revenue, however, on a consolidated basis rose to Rs 1,894 crore for the quarter under consideration as against Rs 1,417 crore for the same period a year ago.

The company’s net profit was impacted as depreciation and amortisation was higher by Rs 68 crore on account of acquired business, one time impact of product recall in US of Rs 25 crore and lower hedging gains due to rupee depreciation, Torrent Pharmaceuticals said.

The research and development spend for the second quarter this fiscal was also higher at Rs 136 crore as against Rs 107 crore in the year ago period, it added.

  • Related Posts

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states